Status:
COMPLETED
Medication Use Evaluation for Enoxaparin in Hospitalized COVID-19 Patients
Lead Sponsor:
Methodist Health System
Conditions:
Venous Thromboembolism
Eligibility:
All Genders
18+ years
Brief Summary
Retrospective chart review to be conducted at Methodist Richardson Medical Center (MRMC) in Richardson, TX. All adult patients hospitalized with COVID-19 on enoxaparin for DVT prophylaxis will be incl...
Detailed Description
Retrospective chart review to be conducted at Methodist Richardson Medical Center (MRMC) in Richardson, TX. All adult patients hospitalized with COVID-19 on enoxaparin for DVT prophylaxis will be incl...
Eligibility Criteria
Inclusion
- Effectiveness of intermediate-intensity vs standard prophylactic enoxaparin regimens on preventing DVT and/or PE in patients with COVID-19, measured using the following variables:
- Enoxaparin dose (appropriate for kidney function)
- Charlson comorbidity index (CCI) score
- Padua prediction score for risk of VTE
- IMPROVE \[International Medical Prevention Registry on VTE\] bleeding risk assessment score
- ICU status
- Number of thromboembolic events
- Length of stay
- Readmissions for DVT and/or PE
- In-hospital mortality with associated DVT or PE
Exclusion
- Safety of intermediate-intensity vs standard prophylactic enoxaparin regimens in patients with COVID-19, measured using the following variables:
- Bleeding events
- Type of bleeding event
Key Trial Info
Start Date :
November 17 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 22 2025
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT05226793
Start Date
November 17 2021
End Date
July 22 2025
Last Update
July 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Methodist Richardson Medical Center
Richardson, Texas, United States, 75082